The Asia Pacific Analgesics Market would witness market growth of 7.2% CAGR during the forecast period (2022-2028).
Patients in pain should receive the most effective treatment possible. Outside of current palliative care, cancer treatment, and end-of-life care, opioids are not the primary medication for chronic pain. Non-opioid treatments, such as non-opioid drugs and nonpharmacological therapy, can relieve chronic pain while also being safer. To the degree practicable, non-opioid therapy should be used in the treatment of chronic pain. Identify and treat co-occurring mental health issues. Preferentially use first-line drug options. In patients who have failed non-invasive treatments, consider interventional therapies, such as corticosteroid injections
Non-opioid pain relievers, such as ibuprofen, acetaminophen, aspirin, and steroids are available over the counter or through prescriptions, and some people find that these are sufficient. Nondrug therapy, which can be used solely or in combination with drugs, helps some patients. A physician who specializes in physical medicine, as well as rehabilitation, may be able to design an exercise program for patients that improves their functional abilities while also reducing pain.
Consumers in numerous regional countries are less concerned with analgesic side effects. Self-medication rather than consulting a skilled physician for moderate pain and fever is a habit that is prevalent in a number of nations, most notably in India. Furthermore, consumers in most urban areas in the region are seeking quick and easy ways to relieve pain due to their extremely stressed lifestyles. This, together with the increase in purchasing power, has allowed analgesic demand and sales to increase over time. China is one of the largest pharmaceutical markets in the world, and it is thriving as a result of two primary factors, including large-scale capital investment and rapid productivity growth. These two factors indicate that the country would be a lucrative investment destination as well as a significant source of domestic savings. Since the 1970s, the country has been shifting from a low-income to a more market-oriented economy. China is experiencing a spike in the regional market due to its large-scale production capability and high analgesics consumption.
The China market dominated the Asia Pacific Analgesics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,391 Million by 2028. The Japan market is experiencing a CAGR of 6.5% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 7.8% during (2022 - 2028).
Based on Type, the market is segmented into Non-opioids and Opioids. Based on Route of Administration, the market is segmented into Oral, Transdermal, Intravenous, Topical, and Rectal. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Analgesics Market is Projected to reach USD 42.6 Billion by 2028, at a CAGR of 6.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Reckitt Benckiser Group PLC, Abbott Laboratories, Johnson & Johnson, Bayer AG, Endo International PLC, GlaxoSmithKline PLC, Pfizer, Inc., Sanofi S.A., and Eli Lilly And Company.
By Type
By Route of Administration
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 